Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab

Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab

Abstract The ability of patients with hematologic malignancies (HM) to develop an effective humoral immune response after COVID-19 is unknown. A prospective study was performed to monitor the immune response to SARS-CoV-2 of patients with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBC...

Full description

Bibliographic Details
Main Authors: C. Cattaneo, V. Cancelli, L. Imberti, K. Dobbs, A. Sottini, C. Pagani, A. Belotti, A. Re, A. Anastasia, V. Quaresima, A. Tucci, J. A. Chiorini, H. C. Su, J. I. Cohen, P. D. Burbelo, G. Rossi, L. D. Notarangelo
Format: Article
Language:English
Published: Nature Publishing Group 2021-09-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-021-00546-9

Internet

https://doi.org/10.1038/s41408-021-00546-9

Similar Items